Experience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada
|
|
- Samson Shaw
- 5 years ago
- Views:
Transcription
1 Experience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada Jessica MacNeil, MPH Epidemiologist Centers for Disease Control and Prevention (CDC) March 19, 2012 National Center for Immunization & Respiratory Diseases Meningitis and Vaccine Preventable Diseases Branch
2 Presentation Goals Understand the epidemiology and burden of meningococcal disease in the US and Canada Understand US adolescent meningococcal vaccination recommendations and use of MenACWY in Canada Describe the impact of routine adolescent meningococcal vaccination on US disease burden
3 EPIDEMIOLOGY AND BURDEN OF MENINGOCOCCAL DISEASE
4 Rate per 100,000 Meningococcal Disease Incidence, United States, Current incidence: US*: 0.3 cases/100,000 population Canada**: 1 case/100,000 population Year * NNDSS data, ABCs data estimated to U.S. population **
5 Rate per 100,000 Incidence Declines Observed in All Serogroups, United States, B C Y W MenACWY 0 Year ABCs cases from estimated to the U.S. population with 18% correction for under reporting
6 Incidence of Meningococcal Disease by Serogroup, Canada, MenC Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations (accessed March 13, 2012)
7 A Comparison of the Epidemiology Similarities: Rates of serogroup B are highest in children <5 years 60-70% of disease caused by serogroup B Serogroups C and Y more common in adolescents and adults Differences: Serogroup Y emerged in the US in the late 1990 s Associated with bacteremic pneumonias in older adults Serogroup distribution and rates vary slightly
8 MENINGOCOCCAL VACCINES AND RECOMMENDATIONS
9 Meningococcal Vaccines in Canada Vaccine MenC (3 available vaccines; first licensed in 2002) MenACWY (Menactra licensed 2007; Menveo licensed 2010) Suggested Uses One dose in second year of life (12 months) For infants at increased risk, a dose at two, four, and 12 months of age Adolescent booster Adolescent booster After age two in groups at increased risk Vaccination programs differ by province. As of December 2010 all provinces and territories had implemented publicly funded, universal MenC vaccination programs for young children. (accessed February 27, 2012)
10 Summary of US Meningococcal Vaccine Recommendations Group Primary Series* Booster Dose* Adolescents aged years Persons aged 2-55 years at high-risk** 1 dose, preferably at age years HIV-infected adolescents: 2 doses, 8 to 12 weeks apart 2 doses, 8 to 12 weeks apart 1 dose for microbiologists and travelers Age 16 years if primary dose at age years During ages of primary dose at age years No booster needed if primary dose on or after age 16 years Age 2-6 years: 3 years Age 7 years: 5 years Persons aged 9-23 months at high-risk** 2 doses, 8 to 12 weeks apart *Two licensed MenACWY vaccines: Menactra in 2005 and Menveo in 2010 **High-risk includes persistent complement deficiency, functional or anatomic asplenia, or prolonged increased risk of exposure
11 Differing Vaccination Strategies Canada s meningococcal vaccine program focuses on young children and uses primarily MenC MenACWY can be used as a booster dose in adolescents High-risk individuals after age 2 years The US meningococcal vaccine program is an adolescent program using MenACWY Adolescent booster dose added in 2011 MenACWY also used for high-risk individuals 9 months-55 years
12 US ADOLESCENT VACCINE PROGRAM AND IMPACT ON DISEASE BURDEN
13 2005 US Meningococcal Vaccination Recommendations Goal: Protect adolescents through peak in disease seen in year-olds Assumptions: Vaccine would protect most adolescents for 10 years Vaccination at years of age preferred High coverage prior to increased period of risk Adolescent vaccination platform
14 Rate per 100,000 Rates of Meningococcal Disease (C and Y) by Age, Serogroup C Serogroup Y Period of risk Age (years) *Active Bacterial Core surveillance (ABCs), estimated to the US population
15 Percent Coverage Coverage of 1-dose MenACWY among year-olds, NIS-Teen, * Age (years) National Immunization Survey Teen In 2010, MenACWY coverage varied from 26-90% by state
16 Rates of Serogroup C,Y,W135 Meningococcal Disease* Year Rate per 100,000 (95% confidence intervals) year-olds 20 year-olds 2004 and (0.15, 0.35) 0.16 (0.13, 0.20) 2006 and (0.18, 0.40) 0.22 (0.18, 0.26) 2008 and (0.08, 0.24) 0.21 ( ) *Active Bacterial Core surveillance, estimated to the U.S. population
17 Average Annual Number of Cases of C,Y,W135 Meningococcal Disease Age Group Percent Change yrs % yrs % yrs % Total (11-22 yrs) % *Active Bacterial Core surveillance, estimated to the US population
18 Meningococcal Disease Among Persons Previously Vaccinated Reports of over 40 cases of meningococcal disease among persons who received MenACWY Case-fatality ratio of vaccinated cases high (20%) Increasing number of vaccinated cases occurring 2-5 years after vaccination
19 Preliminary Menactra VE Estimates, Case-Control Study, Duration of Protection* Cases (n=147)* VE (95% CI) Vaccinated <1 year 79% (46, 92%) Vaccinated 1-2 years 73% (32, 89%) Vaccinated 3 years 43% (-1, 68%) *Analysis results based on paperwork received by December 31, Controls for smoking status and underlying condition status PRELIMINARY RESULTS, SUBJECT TO CHANGE. PLEASE DO NOT DISTRIBUTE
20 % >= 1:128 SBA-BR Seroresponse 1:128 Post-Vaccination, Serogroup C MenACWY (Menactra) MPSV Age-matched naive n= 440, 441 n= 71, 72, 84 n= 108, 207, mo 3 years 5 years Time post-vaccination *Data courtesy of sanofi pasteur, 3 year follow-up of MTA02 (11-18 year-olds), 5 year follow-up of (2-10 year-olds)
21 SBA-BR GMT (log scale) SBA-BR Pre- and Post-Booster: Serogroup C MenACWY (Menactra) MPSV4 Naïve n= 440, 441 n= 108, 207, 107 n= 55, 56 1 month 5 years, pre-vac 5 years, post-vac *Data courtesy of sanofi pasteur, 5 year follow-up of (11-18 year-olds at dose 1)
22 hsba Seroresponse 1:8 Post-Vaccination, Serogroup C Age group (yrs) at vaccination 11 through 18 years Years post vaccination Serogroup C SBA Vaccine No. of vaccine recipients in study 2 % hsba 1:8 Menveo % Menactra % Recipients with protective antibody levels *Data courtesy of Novartis
23 Rationale: 2011 Booster Dose Recommendations Optimize protection through late adolescence Expectation that antibody decline will not be as rapid after the booster dose Increase potential for herd immunity
24 MenACWY Impact on Disease Burden, United States Measuring vaccine impact is challenging because of low disease burden Incidence declined from 0.41 to 0.27/100,000 during Vaccination coverage varies by state (2010: 26-90% in y.o.) Correlation between increasing vaccine coverage and decreasing disease incidence seen in year olds No correlation between adolescent vaccine coverage and disease incidence in <5 year olds and 25 year olds States with more rapid uptake of MenACWY have achieved greater declines in meningococcal disease incidence in adolescents
25 Future Strategies: Do We Need an Infant Meningococcal Program in the United States? Impact of adolescent program not fully realized Disease rates continue to decline in infants in the absence of vaccination Epidemiology in infants makes disease prevention difficult in this age group High proportion of serogroup B disease Highest rates of disease prior to 6 months of life
26 Number of Cases Estimated Annual Number of Cases of Meningococcal Disease, United States: Age 0-21 years Serogroups A,C,Y,W-135 Serogroup B 0 < Age (Years) *Active Bacterial Core surveillance, estimated to the US population
27 Thank you! For more information please contact Centers for Disease Control and Prevention 1600 Clifton Road NE, Atlanta, GA Telephone, CDC-INFO ( )/TTY: Web: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. National Center for Immunizations and Respiratory Diseases Meningitis and Vaccine Preventable Diseases Branch
Meningococcal Vaccine Policies among Colleges and Universities United States, 2017
National Center for Immunization & Respiratory Diseases Meningococcal Vaccine Policies among Colleges and Universities United States, 2017 Sara Oliver MD, MSPH Medical Epidemiologist National Immunization
More information9/12/2018. Meningococcal Disease and Meningococcal Vaccine. Neisseria meningitidis. Meningococcal Disease Pathogenesis. Aerobic gram-negative bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Meningococcal Disease and Meningococcal Vaccine Adult Track Chapter 14 Photographs and images included
More informationMeningococcal Update. Disclosure. Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting
1 Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting 2 Disclosure Speakers Bureau: Sanofi Pasteur Vaccines and Novartis! I do not intend to discuss an unapproved/
More informationImmunization Update. William Atkinson, MD, MPH. Immunization Action Coalition
Immunization Update William Atkinson, MD, MPH Immunization Action Coalition Coordinated School Health Conference Lake Ozark, Missouri December 3, 2016 1 Disclosures William Atkinson has no financial relationships
More informationWHAT S NEW WITH VACCINATIONS IN 2016?
WHAT S NEW WITH VACCINATIONS IN 2016? MenB and a Few Other Changes Lynn Bahta, RN, PHN Immunization Clinical Consultant Minnesota Department of Health May 2016 Disclosure No conflict of interest Will discuss
More informationImmunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012
Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants
More informationPlatforms. Adolescent Immunization Update and the 16 Year Old Platform. Advisory Committee on Immunization Practices (ACIP)
Adolescent Immunization Update and the 16 Year Old Platform William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition Advisory Committee on Immunization Practices
More informationACIP Recommendation Update. Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego
ACIP Recommendation Update Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego What has ACIP been up to lately? New Recommendations Tdap vaccination for each pregnancy Meningococcal
More information2017 Vaccination Update
2017 Vaccination Update NATHAN BOONSTRA, MD General Pediatrician, Blank Pediatric Clinic TODAY S OBJECTIVES Review the latest recommendations for immunizations, including HPV Meningococcal vaccines Influenza
More informationAndrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010
2010 Immunization Update Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010 Disclosures No financial conflict
More informationVACCINE-PREVENTABLE DISEASES (VPDS): CURRENT TRENDS
VACCINE-PREVENTABLE DISEASES (VPDS): CURRENT TRENDS Adult Immunization Conference April 10, 2018 Steve Fleming, EdM stephen.fleming@state.ma.us Presenter Disclosure Information I, Steve Fleming, have been
More informationPrevention and Control of Meningococcal Disease
Morbidity and Mortality Weekly Report / Vol. 62 / No. 2 March 22, 2013 Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP) Continuing
More informationS404- Meningococcal Vaccines: Updated Policy Statement 2014
S404- Meningococcal Vaccines: Updated Policy Statement 2014 Michael T. Brady, MD Associate Medical Director Nationwide Children s Hospital Columbus, Ohio Disclosure of Relevant Relationship Dr. Brady (or
More informationUsing Cancer Registry Data for Post Marketing Surveillance of Rare Cancers
Using Cancer Registry Data for Post Marketing Surveillance of Rare Cancers Hannah K Weir, PhD Epidemiology and Applied Research Branch Division of Cancer Prevention and Control CDC NAACCR Annual Conference
More informationVaccine knowledge, attitudes, and informationseeking behavior of parents of adolescents: United States, 2012
Vaccine knowledge, attitudes, and informationseeking behavior of parents of adolescents: United States, 2012 Allison Kennedy Fisher, MPH Katherine LaVail, PhD National Conference on Health Communication,
More informationUpdate on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017
Centers for for Disease Disease Control Control and and Prevention Prevention National Center for Immunization and Respiratory Diseases Update on Vaccine Recommendations New Horizons in Pediatrics April
More informationSplenectomy Vaccine Protocol PIDPIC
Splenectomy Vaccine Protocol PIDPIC 6.24.14 Rationale Spleen clears encapsulated bacteria and infected erythrocytes Serves as one of the largest lymphoid tissues where B cells are educated against encapsulated
More informationThyroid cancer in the United States: Recent increases
Thyroid cancer in the United States: Recent increases Meg Watson Epidemiology and Applied Research Branch Division of Cancer Prevention and Control CDC NAACCR Annual Conference June 22, 2011 National Center
More informationHyporesponsiveness: Time To Stop Using Meningococcal Polysaccharide Vaccines?
Hyporesponsiveness: Time To Stop Using Meningococcal Polysaccharide Vaccines? Lee H. Harrison, M.D. Professor of Medicine and Epidemiology University of Pittsburgh First Regional Meningococcal Symposium
More informationRecommendations for Using Pneumococcal Vaccines among Adults
Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar February 2016 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationThe Childhood Immunization Schedule and the National Immunization Survey
The Childhood Immunization Schedule and the National Immunization Survey Melinda Wharton, MD, MPH Deputy Director, National Center for Immunization & Respiratory Diseases Institute of Medicine 9 February
More informationMeningococcal Disease and College Students
MASSACHUSETTS PUBLIC HEALTH FACT SHEET Meningococcal Disease and College Students May 2018 Page 1 of 4 What is meningococcal disease? Meningococcal disease is caused by infection with bacteria called Neisseria
More informationDisclosure Statement. Encapsulated Bacteria. Functions of the Spleen 10/25/2017. Pharmacist Learning Objectives
Pharmacist Learning Objectives No Spleen? No Problem. A Review of Vaccinations Indicated for the Asplenic Patient SCSHP Fall Meeting October 26, 2017 Explain the rationale for vaccinations in Select the
More informationUpdate ACIP Influenza Vaccination Recommendations for
Update ACIP Influenza Vaccination Recommendations for 2014-15 Lisa Grohskopf, MD, MPH Influenza Division, CDC IAC Webinar 11 September 2014 National Center for Immunization and Respiratory Diseases Influenza
More informationCDC Programmatic Activities in Breast and Ovarian Cancer Genomics
CDC Programmatic Activities in Breast and Ovarian Cancer Genomics Katrina F. Trivers, PhD, MSPH Epidemiologist Division of Cancer Prevention and Control CDC The First Line of Defense: Application of Breast
More informationMENINGITIS WHAT S NEW? 3 RD NOVEMBER 2018
MENINGITIS WHAT S NEW? 3 RD NOVEMBER 2018 CONFLICTS OF INTEREST Educational travel grant - Gilead JIM NEWCOMBE FRCPA FRACP ID PHYSICIAN, ROYAL NORTH SHORE HOSPITAL, SYDNEY CLINICAL MICROBIOLOGIST, DOUGLASS
More informationPneumococcal Disease and Pneumococcal Vaccines
Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at
More informationRecommendations for Using Pneumococcal Vaccines among Adults
Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar July 2017 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases
More informationDecision-making for introduction of meningococcal vaccines in the face of changing meningococcal epidemiology
Decision-making for introduction of meningococcal vaccines in the face of changing meningococcal epidemiology Wiebke Hellenbrand Frankfurt, November 1, 2016 Evidence-based approach to vaccination recommendations
More informationBACTERIAL MENINGITIS IN CHILDREN
Overview Bacterial meningitis in children : rare, severe, mostly preventable What should GPs advise Australian parents in 2018? Peter McIntyre Professorial Fellow, National Centre for Immunisation Research
More information5/14/2015. Meagan Burns, MPH Massachusetts Adult Immunization Conference April relevant conflict. Grant Research/Support
Meagan Burns, MPH Massachusetts Adult Immunization Conference April 2015 Consultant Grant Research/Support Speaker s Bureau Major Stockholder Other Financial or Material Interest Off Label Use of Vaccines
More informationHemagglutinin Neuraminidase
Evolving Vaccine Guidance: Influenza, Meningococcal & HPV Vaccines H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Maine Chapter AAP Bar Harbor, Maine October 16, 2016
More informationMortality Slide Series. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention
Mortality Slide Series National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention HIV Mortality Slides An analysis of trends in rates and distributions of deaths
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE August 30, 2010 EFFECTIVE DATE August 30, 2010 MEDICAL ASSISTANCE BULLETIN NUMBER 01-10-27, 08-10-28, 09-10-29, 31-10-30, 33-10-05 SUBJECT: Updates to the Medical Assistance Program Fee Schedule
More informationSource: Portland State University Population Research Center (
Neisseria meningitidis Surveillance Report 2009 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated: June 2011 Background The Active
More informationDecision-making by the Advisory Committee on Immunization Practices
Decision-making by the Advisory Committee on Immunization Practices Melinda Wharton, MD, MPH Deputy Director, National Center for Immunization & Respiratory Diseases Institute of Medicine 9 February 2012
More informationMandates and More. Julie Morita, M.D. Deputy Commissioner Chicago Department of Public Health. Chicago Department of Public Health
Mandates and More Julie Morita, M.D. Deputy Chicago Department of Public Health Why are vaccines required for school entry? School Vaccine Requirements Small pox vaccine required in Massachusetts 1855
More informationKeeping up with the immunization schedule: Meningococcal and More
Keeping up with the immunization schedule: Meningococcal and More DatTran, MD, MSc, FRCPC, FAAP Division of Infectious Diseases, The Hospital for Sick Children Department of Paediatrics, University of
More informationAdolescent Immunizations
Adolescent Immunizations Preteen Vaccine Week Webinar January 23, 2008 Eileen Yamada, MD, MPH California Department of Public Health Immunization Branch Younger Children AND Adolescents Need Immunizations!
More informationImmunization Update Disclosures. Candice Robinson, MD, MPH Medical Officer Immunization Services Division 5/12/2017
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Immunization Update 2017 Candice Robinson, MD, MPH Medical Officer Immunization Services Division Western
More informationImproving HPV Vaccine Coverage Why We Must and How We Can Do Better
National Center for Immunization & Respiratory Diseases Improving HPV Vaccine Coverage Why We Must and How We Can Do Better Melinda Wharton, MD, MPH Director, Immunization Services Division Illinois State
More information2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS
IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient
More informationImmunization Update 2017 Adult Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH
Immunization Update 2017 Adult Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Highlighted Topics Influenza Vaccine Errors 2 Dose HPV Community protection Tdap in pregnancy Meningococcal Future Recs
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on CPS Meningococcal Vaccination These podcasts are designed to give medical students an overview of key topics in pediatrics.
More informationMDPH Clinical Update Adult Coalition
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences MDPH Clinical Update Adult Coalition 1-9-2018 Susan M. Lett, MD, MPH Medical Director, Immunization Program
More informationZika Virus Communication Media Talking Points
Zika Virus Communication Media Talking Points Benjamin Haynes Senior Press Officer, News Media Branch, CDC Department of Health and Human Services Centers for Disease Control and Prevention Media Talking
More informationThe State of Asthma. Jeanne Moorman, NCEH Survey Statistician National Asthma Program
The State of Asthma American College of Chest Physicians 14th Annual ACCP Community Asthma and COPD Coalitions Symposium October 24-25, 212 Atlanta, GA Jeanne Moorman, NCEH Survey Statistician National
More informationInfluenza Update. Lisa Grohskopf, MD, MPH Influenza Division, CDC. NAICP Call 6 October 2015
Influenza Update Lisa Grohskopf, MD, MPH Influenza Division, CDC NAICP Call 6 October 2015 National Center for Immunization and Respiratory Diseases Influenza Division Overview Surveillance update ACIP
More informationComparing Definitions of Current and Active Asthma: An Analysis of BRFSS Asthma Call-back Survey (ACBS) Data
Comparing Definitions of Current and Active Asthma: An Analysis of BRFSS Asthma Call-back Survey (ACBS) Data Cara Person, MPH, CPH CSTE Conference June 5, 2012 National Center for Environmental Health;
More information14-ID-06. Revision of the National Surveillance Case Definition for Meningococcal Disease
14-ID-06 Committee: Infectious Disease Title: Revision of the National urveillance Case Definition for Meningococcal Disease I. tatement of the Problem The current case definition for meningococcal disease,
More informationImmunization Guidelines for the Use of State Supplied Vaccine May 17, 2015
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationESCMID Online Lecture Library
What would be the best schedule for prevention of meningococcal disease in all ages? Ray Borrow ray.borrow@phe.gov.uk Public Health England, Manchester, UK MCC vaccine programme - UK In November 1999,
More informationPertussis Epidemiology and Vaccine Impact in the United States
Pertussis Epidemiology and Vaccine Impact in the United States Stacey Martin, MSc Epidemiology Team Lead Meningitis and Vaccine Preventable Diseases Branch Centers for Disease Control and Prevention Presented
More informationImmunization Update & focus on meningococcal vaccine PART 2
Immunization Update & focus on meningococcal vaccine PART 2 Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases University of Cape Town www.vacfa.uct.ac.za Meningococcal Disease
More informationShelter-based Meningococcal Disease Outbreak: Working together to treat and vaccinate
Shelter-based Meningococcal Disease Outbreak: Working together to treat and vaccinate Barbara Giles, MSN, RN April Donahue, BSN, RN Denise De Las Nueces, MD, MPH Boston Health Care for the Homeless Program
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH Immunization Action Coalition Kentucky Immunization Conference Louisville, Kentucky October 14, 2015 Information in this presentation are valid as of
More informationSTOP. Meningococcal Vaccination. Improving Rates in Adolescents and Reducing Racial, Ethnic and Socioeconomic Disparities. Call to Action MENINGITIS
Meningococcal Vaccination Improving Rates in Adolescents and Reducing Racial, Ethnic and Socioeconomic Disparities Call to Action STOP SHARE. TEACH. OUTREACH. PROTECT. MENINGITIS Supported by an unrestricted
More informationUpdate of the CDC/HICPAC Guideline: Infection Prevention in Healthcare Personnel
Update of the CDC/HICPAC Guideline: Infection Prevention in Healthcare Personnel David T. Kuhar, M.D. Medical Epidemiologist HICPAC Meeting June 6, 2013 National Center for Emerging and Zoonotic Infectious
More information10/19/2011. Burden. Capacity. Core Violence and Injury Prevention Program: Developing S.M.A.R.T. Objectives. Moving the Needle
Core Violence and Injury Prevention Program: Developing S.M.A.R.T. Objectives Christopher D. Jones, PhD Core VIPP Evaluation Team October 19, 2011 National Center for Injury Prevention and Control Division
More informationMeningococcal disease and vaccination in the UK
Meningococcal disease and vaccination in the UK Ray Borrow Professor of Vaccine Preventable Diseases, Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester, U.K. ray.borrow@hpa.org.uk
More informationNovartis receives FDA approval of Menveo, a vaccine to prevent meningococcal disease
Novartis Vaccines and Diagnostics, Inc 350 Massachusetts Avenue Cambridge, MA 02139 http://www.novartisvaccines.com MEDIA RELEASE MEDIA RELEASE MEDIA RELEASE Novartis receives FDA approval of Menveo, a
More informationSee Spot Run Meningococcal update 2017
See Spot Run Meningococcal update 2017 Jim Buttery Infection and Immunity Monash Children s Hospital Monash Health Monash University SAEFVIC How serious a disease is N meningitidis? Meningococcal disease
More informationReview of Meningococcal Conjugate Vaccine Against Twelve Criteria for School/Facility/College Immunization Requirements
Draft 4/26/10 Oregon School/Facility/College Immunization Advisory Committee: Review of Meningococcal Conjugate Vaccine Against Twelve Criteria for School/Facility/College Immunization Requirements Oregon
More informationImmunization Update 2013 Across the Lifespan
Immunization Update 2013 Across the Lifespan Andrew Kroger M.D., M.P.H. Medical Officer, Centers for Disease Control and Prevention New York State Association of County Health Officials (NYSACHO) New York
More informationReceived 22 May 2009/Returned for modification 7 July 2009/Accepted 29 September 2009
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2009, p. 1810 1815 Vol. 16, No. 12 1556-6811/09/$12.00 doi:10.1128/cvi.00207-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Quadrivalent
More informationWHO Position Paper on Meningococcal Vaccines, Nov 2011
WHO Position Paper on Meningococcal Vaccines, Nov 2011 Extended list of references and summaries for the position paper and associated grading Tables Advisory Committee on Immunization Practices (ACIP).
More informationNational Immunisation Programme changes Michael Baker. Wessex Public Health England Centre
National Immunisation Programme changes 2013-14 Michael Baker Wessex Public Health England Centre Changes to the Meningococcal serogroup C conjugate (MenC) vaccine schedule in 2013 2 Immunisation Programme
More informationImmunization Update 2015
Immunization Update 2015 William Atkinson, MD, MPH* California Immunization Coalition Summit Riverside, California April 26, 2015 *Representing the Immunization Action Coalition, Saint Paul, MN Advisory
More informationHPV Trends: Improving Vaccination Coverage
National Center for Immunization & Respiratory Diseases HPV Trends: Improving Vaccination Coverage Cindy Weinbaum MD MPH Acting Director, Immunization Services Division Texas Immunization Conference San
More informationIntroduction of a meningococcal ACWY immunisation programme for adolescents
Introduction of a meningococcal ACWY immunisation programme for adolescents Information for registered healthcare practitioners Acknowledgement: This resource has been adapted with the permission of Public
More informationCouncil for Outbreak Response: Healthcare-Associated Infections & Antibiotic-Resistant Pathogens (CORHA) HICPAC December 1, 2016
Council for Outbreak Response: Healthcare-Associated Infections & Antibiotic-Resistant Pathogens (CORHA) HICPAC December 1, 2016 National Center for Emerging and Zoonotic Infectious Diseases Division of
More informationMeningococcal Education Program for Quebec Physicians: How Results Have Changed 2 Years after the Initial Program
Meningococcal Education Program for Quebec Physicians: How Results Have Changed 2 Years after the Initial Program Marc H. Lebel, MD, FRCPC John Yaremko, MD, FRCPC Anne Dionne, MD, FRCPC Anne-Julie Gaudreau,
More informationPEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children s Hospital
PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children s Hospital Volume 17 Number 10 October 2011 M An Update on Quadrivalent Meningococcal
More informationVACCINATION CONVERSATION GUIDE
VACCINATION CONVERSATION GUIDE A helpful tool for discussing vaccines with your patients 2017 GSK group of companies. All rights reserved. Produced in USA. 817419R0 February 2017 How this guide works:
More informationInfluenza Surveillance in the United St ates
Influenza Surveillance in the United St ates Scot t Epperson, MPH Surveillance and Outbreak Response Team Influenza Division U.S. Centers for Disease Control and Prevention National Center for Immunization
More informationEstimating RSV Disease Burden in the United States
Estimating RSV Disease Burden in the United States Brian Rha, MD, MSPH Medical Epidemiologist, Division of Viral Diseases Centers for Disease Control and Prevention Severe Acute Respiratory Infection Surveillance
More informationChanges to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25
Changes to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered healthcare practitioners August 2014 Quality Education
More informationVACCINES-WHAT HAS HAPPENED IN THE LAST YEAR. Mark H. Sawyer UCSD School of Medicine Rady Children s Hospital San Diego
VACCINES-WHAT HAS HAPPENED IN THE LAST YEAR Mark H. Sawyer UCSD School of Medicine Rady Children s Hospital San Diego LOTS HAS HAPPENED AND IT CAN BE A LITTLE CONFUSING Some people can get 2 doses of HPV
More informationPneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections
Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths
More informationVaccines for infants- What has happened in the last year?
Vaccines for infants- What has happened in the last year? MARK H. SAWYER UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO Lots has happened and it can be a little confusing Infants used to require
More informationCost-Effectiveness of Quadrivalent vs Monovalent Vaccination against Meningococcal Disease in Canada
Cost-Effectiveness of Quadrivalent vs Monovalent Vaccination against Meningococcal Disease in Canada Derek Weycker, Ph.D. 1 Mark Atwood, M.S. 1 Thomas E. Delea, M.S.I.A. 1 Anoush Youssoufian, B.A. 1 Dion
More informationClinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States
Clinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States Linda Beer, PhD, Christine L. Mattson, PhD, Joseph Prejean, PhD, and Luke Shouse, MD 10 th International
More informationWhose Calling the Shots? - A 2019 Vaccine Update. Frank Bell Swedish Pediatric Infectious Disease Jan 2019
Whose Calling the Shots? - A 2019 Vaccine Update Frank Bell Swedish Pediatric Infectious Disease Jan 2019 2019 Vaccine Update Vaccines Meningococcal serogroup B HPV Pertussis Influenza Children with uncertain
More informationUpdate on the Epidemiology of Meningococcal Disease and Guidance for the Control of Meningococcal Disease Outbreaks in the U.S.
National Center for Immunization & Respiratory Diseases Update on the Epidemiology of Meningococcal Disease and Guidance for the Control of Meningococcal Disease Outbreaks in the U.S. Sarah Meyer, MD MPH
More informationWHO position paper on meningococcal vaccines
WHO position paper on meningococcal vaccines Geneva, Switzerland Published in WER Nov 2011 Epidemiology of meningococcal disease In most countries Neisseria meningi+dis is a leading cause of meningi)s
More informationPertussis Epidemiology and Vaccination in the United States and the Latin American Pertussis Project
Pertussis Epidemiology and Vaccination in the United States and the Latin American Pertussis Project Thomas Clark, MD, MPH Epidemiology Team Lead Meningitis and Vaccine Preventable Diseases Branch National
More informationImmunization Report Public Health September 2013
Immunization Report Public Health September 2013 Daycare, school entry and school program immunization enrollment rates, up to 2012 Table of Contents 1. Introduction... 2 2. Data Source... 2 3. Limitations...
More informationWHY WE RE HERE. Melinda Wharton, MD, MPH Director, Immunization Services Division. National Center for Immunization & Respiratory Diseases
National Center for Immunization & Respiratory Diseases WHY WE RE HERE Melinda Wharton, MD, MPH Director, Immunization Services Division AIM Leadership Conference February 8, 2017 Vaccines save lives.
More informationMeningococcal Disease Prevention
Meningococcal Disease Prevention Strengthening Protection in Adolescents Courtesy of CDC/James Gathany MKT30019 2R Brought to you as a public health service by the Immunization Action Coalition and Sanofi
More informationNHS public health functions agreement Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme
NHS public health functions agreement 2018-19 Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme 1 NHS public health functions agreement 2018-19 Service specification
More informationQ21. Where can I find more information on meningococcal disease and vaccines?
FREQUENTLY ASKED QUESTIONS This fact sheet provides responses to some common questions about meningococcal vaccines, focusing on quadrivalent meningococcal conjugate vaccines (4vMenCVs). More detailed
More informationAdult Vaccine Update. NB Internal Medicine Update, April 22 nd, 2016 Dan Smyth, MD, FRCPC, DTMH
Adult Vaccine Update NB Internal Medicine Update, April 22 nd, 2016 Dan Smyth, MD, FRCPC, DTMH Summary points: Canadian adults > 18 should be regularly assessed to ensure recommended vaccinations are up
More informationDisclosures. Potential conflicts. No off-label use discussion. Safety Review Committee. Data and Safety Monitoring Board
2016 Vaccine Update Clinical Reviews Rochester, Minnesota November 2 and November 16, 2016 Robert M Jacobson, MD, FAAP Medical Director, Mayo Clinic Primary Care Immunization Program Disclosures Potential
More informationCalifornia Immunization Coalition 2018 Summit Karen Smith, MD, MPH, Director California Department of Public Health
California Immunization Coalition 2018 Summit Karen Smith, MD, MPH, Director California Department of Public Health California Department of Public Health 1 It takes a broad coalition of partners to: Stop
More informationOVERVIEW WHY THE TOOL? 5/14/18 ASSESSING HPV IMMUNIZATION TRENDS IN 1 MINUTE WHY THE TOOL? HPV ASSESSMENT TOOL USING THE TOOL TO TAKE ACTION RESOURCES
May 2018 ASSESSING HPV IMMUNIZATION TRENDS IN 1 MINUTE ERIKA LOBE, MPH ADOLESCENT/ADULT IMMUNIZATION COORDINATOR OVERVIEW WHY THE TOOL? HPV ASSESSMENT TOOL USING THE TOOL TO TAKE ACTION RESOURCES WHY THE
More informationHaemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationNational Chlamydia Update
National Chlamydia Update Lizzi Torrone Chlamydia Epidemiologist Surveillance and Data Management Branch Region I, Wells Beach, Maine June 4-5, 2012 National Center for HIV/AIDS, Viral Hepatitis, STD,
More information